Highly Increased 125I-JR11 Antagonist Binding In Vitro Reveals Novel Indications for sst2 Targeting in Human Cancers
暂无分享,去创建一个
[1] J. Holst,et al. N‐terminally and C‐terminally truncated forms of glucose‐dependent insulinotropic polypeptide are high‐affinity competitive antagonists of the human GIP receptor , 2016, British journal of pharmacology.
[2] E. Mittra,et al. 177-Lu-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors : Results of the Phase III NETTER-1 Trial , 2016 .
[3] J. Reubi,et al. Triple-Peptide Receptor Targeting In Vitro Allows Detection of All Tested Gut and Bronchial NETs , 2015, The Journal of Nuclear Medicine.
[4] J. Reubi,et al. Does Somatostatin or Gastric Inhibitory Peptide Receptor Expression Correlate with Tumor Grade and Stage in Gut Neuroendocrine Tumors? , 2015, Neuroendocrinology.
[5] W. Weber,et al. Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study , 2014, The Journal of Nuclear Medicine.
[6] R. Baum,et al. Molecular imaging of late somatostatin receptor-positive metastases of renal cell carcinoma in the pancreas by 68Ga DOTATOC PET/CT: a rare differential diagnosis to multiple primary pancreatic neuroendocrine tumors. , 2014, Clinical nuclear medicine.
[7] J. Reubi,et al. Evaluation of 177Lu-DOTA-sst2 Antagonist Versus 177Lu-DOTA-sst2 Agonist Binding in Human Cancers In Vitro , 2011, The Journal of Nuclear Medicine.
[8] V. Ambrosini,et al. Radiopeptide Imaging and Therapy in Europe , 2011, The Journal of Nuclear Medicine.
[9] Matthias Briel,et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] E. Krenning,et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. , 2010, Gastroenterology.
[11] J. Reubi,et al. Highly Efficient In Vivo Agonist-Induced Internalization of sst2 Receptors in Somatostatin Target Tissues , 2009, Journal of Nuclear Medicine.
[12] E. Krenning,et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Anastasia Nikolopoulou,et al. Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting , 2008, Journal of Nuclear Medicine.
[14] G. Antoch,et al. Somatostatin receptor scintigraphy in advanced renal cell carcinoma , 2008, Nuklearmedizin.
[15] Judit Erchegyi,et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors , 2006, Proceedings of the National Academy of Sciences.
[16] J. Laissue,et al. Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography , 2000, Breast Cancer Research and Treatment.
[17] J. Reubi. Peptide receptors as molecular targets for cancer diagnosis and therapy. , 2003, Endocrine reviews.
[18] J. Reubi,et al. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[19] J. Reubi,et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.
[20] W. Vale,et al. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. , 1999, The Journal of pharmacology and experimental therapeutics.
[21] L. Mazzucchelli,et al. Local up-regulation of neuropeptide receptors in host blood vessels around human colorectal cancers. , 1996, Gastroenterology.
[22] A. Sleight,et al. Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities. , 1996, Biochemical pharmacology.
[23] S. Nilsson,et al. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. , 1995, Cancer research.
[24] J. Reubi,et al. Somatostatin receptors in human prostate and prostate cancer. , 1995, The Journal of clinical endocrinology and metabolism.
[25] J. Laissue,et al. Expression of Somatostatin Receptors in Normal, Inflamed, and Neoplastic Human Gastrointestinal Tissues , 1994, Annals of the New York Academy of Sciences.
[26] J. Jeekel,et al. Somatostatin-receptor scintigraphy in primary breast cancer , 1994, The Lancet.
[27] E. Krenning,et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. , 1993, The Journal of clinical endocrinology and metabolism.
[28] E. Krenning,et al. Somatostatin analogue scintigraphy of malignant lymphomas , 1993, British journal of haematology.
[29] L. Kvols,et al. Somatostatin receptors in human renal cell carcinomas. , 1992, Cancer research.
[30] E. Krenning,et al. in vitro and in vivo detection of somatostatin receptors in human malignant lymphomas , 1992, International journal of cancer.
[31] B. Franc,et al. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[32] J. Charboneau,et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. , 1990, Cancer research.
[33] J. Klijn,et al. Somatostatin receptors in human endocrine tumors. , 1987, Cancer research.